NASDAQ:EPZM - Epizyme Stock Price, Price Target & More

$15.80 -0.05 (-0.32 %)

(As of 04/23/2018 11:42 AM ET)

Previous Close$15.85

Today's Range$15.70 - $16.35

52-Week Range$9.30 - $21.40

Volume48,781 shs

Average Volume428,512 shs

Market Capitalization$1.10 billion

P/E Ratio-7.27

Dividend YieldN/A

Beta1.95

About Epizyme (NASDAQ:EPZM)

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL. It has collaboration agreements with Celgene Corporation, Genentech Inc., and Glaxo Group Limited, as well as with Roche Molecular Systems, Inc., Eisai Co. Ltd., and Lymphoma Study Association. Epizyme, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Receive EPZM News and Ratings via Email

Sign-up to receive the latest news and ratings for EPZM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:EPZM

CUSIPN/A

Webwww.epizyme.com

Phone617-229-5872

Debt

Debt-to-Equity RatioN/A

Current Ratio11.59%

Quick Ratio11.59%

Price-To-Earnings

Trailing P/E Ratio-7.27

Forward P/E Ratio-6.64

P/E GrowthN/A

Sales & Book Value

Annual Sales$10 million

Price / Sales109.78

Cash FlowN/A

Price / CashN/A

Book Value$3.40 per share

Price / Book4.65

Profitability

EPS (Most Recent Fiscal Year)($2.18)

Net Income$-134,300,000.00

Net MarginsN/A

Return on Equity-64.88%

Return on Assets-51.70%

Miscellaneous

Employees131

Outstanding Shares69,480,000

How to Become a New Pot Stock Millionaire

Epizyme (NASDAQ:EPZM) Frequently Asked Questions

What is Epizyme's stock symbol?

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

How were Epizyme's earnings last quarter?

Epizyme (NASDAQ:EPZM) announced its quarterly earnings results on Tuesday, March, 13th. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating the Zacks' consensus estimate of ($0.57) by $0.05. The firm's quarterly revenue was down 100.0% compared to the same quarter last year. View Epizyme's Earnings History.

When is Epizyme's next earnings date?

Epizyme is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Epizyme.

What price target have analysts set for EPZM?

12 Wall Street analysts have issued 12 month price objectives for Epizyme's stock. Their predictions range from $16.00 to $27.00. On average, they anticipate Epizyme's stock price to reach $23.6364 in the next twelve months. View Analyst Ratings for Epizyme.

What are Wall Street analysts saying about Epizyme stock?

Here are some recent quotes from research analysts about Epizyme stock:

1. According to Zacks Investment Research, "Epizyme reported narrower than expected loss in the fourth quarter of 2017. Epizyme's efforts on developing its lead candidate, tazemetostat, for a number of hematological malignancies and genetically defined solid tumors are impressive. During the fourth quarter of 2017, the company had a productive interaction with the FDA to design the registration strategy for tazemetostat for epithelioid sarcomaand follicular lymphoma (FL) and identified a path to submit for accelerated approval for both the indications. The company plans to file a first new drug application of tazemetostat for epithelioid sarcoma in fourth quarter of 2018 and second NDA for FL in 2019. A potential approval for the candidate will be a significant boost for the company. So far this year, Epizyme’s share price has also outperformed the industry. However, the company is highly dependent on its collaboration partners for top-line growth with no approved product." (3/16/2018)
2. Cann analysts commented, "Epizyme presented two posters at the American Society of Hematology Meeting on December 10-11, 2017. These included a biomarker study in non-Hodgkin’s lymphoma (NHL) and preliminary response data from the diffuse large B cell lymphoma (DLBCL) cohort from the ongoing phase II study of tazemetostat in NHL. The data presented is very supportive of our outlook." (12/12/2017)

Who are some of Epizyme's key competitors?

Some companies that are related to Epizyme include Global Blood Therapeutics (GBT), Portola Pharmaceuticals (PTLA), AnaptysBio (ANAB), Medicines (MDCO), Motif (MTFB), Intercept Pharmaceuticals (ICPT), Corcept Therapeutics (CORT), Esperion Therapeutics (ESPR), Spectrum Pharmaceuticals (SPPI), Arena Pharmaceuticals (ARNA), Aimmune Therapeutics (AIMT), Cambrex (CBM), Insmed (INSM), MyoKardia (MYOK), Phibro Animal Health (PAHC), Akcea Therapeutics (AKCA), OPKO Health (OPK) and Madrigal Pharmaceuticals (MDGL).

Who are Epizyme's key executives?

Epizyme's management team includes the folowing people:

Mr. Robert B. Bazemore Jr., Pres, CEO, Sec. & Director (Age 50)
Dr. H. Robert Horvitz Ph.D., M.D., Co-Founder and Chairman of the Scientific Advisory Board
Dr. Yi Zhang Ph.D., Scientific Co-Founder and Member of The Scientific Advisory Board
Mr. Matthew E. Ros, Chief Operating Officer (Age 51)
Dr. Michael Boretti Ph.D., VP of Bus. Devel.

Has Epizyme been receiving favorable news coverage?

Media coverage about EPZM stock has been trending somewhat positive this week, according to Accern Sentiment. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Epizyme earned a media sentiment score of 0.00 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 45.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Epizyme?

Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Epizyme's stock price today?

One share of EPZM stock can currently be purchased for approximately $15.80.

How big of a company is Epizyme?

Epizyme has a market capitalization of $1.10 billion and generates $10 million in revenue each year. The biopharmaceutical company earns $-134,300,000.00 in net income (profit) each year or ($2.18) on an earnings per share basis. Epizyme employs 131 workers across the globe.

How can I contact Epizyme?

Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected]

MarketBeat Community Rating for Epizyme (EPZM)

Community Ranking:		3.1 out of 5 ( )
Outperform Votes:		304 (Vote Outperform)
Underperform Votes:		190 (Vote Underperform)
Total Votes:		494

MarketBeat's community ratings are surveys of what our community members think about Epizyme and other stocks. Vote "Outperform" if you believe EPZM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPZM will underperform the S&P 500 over the long term. You may vote once every thirty days.

Epizyme (NASDAQ:EPZM) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

12 Wall Street analysts have issued ratings and price targets for Epizyme in the last 12 months. Their average twelve-month price target is $23.6364, suggesting that the stock has a possible upside of 49.60%. The high price target for EPZM is $27.00 and the low price target for EPZM is $16.00. There are currently 1 hold rating and 11 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.92	2.92	2.91	3.00
Ratings Breakdown:	0 Sell Rating(s) 1 Hold Rating(s) 11 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 12 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 10 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 11 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$23.6364	$23.6364	$22.6667	$24.25
Price Target Upside:	49.60% upside	24.08% upside	81.33% upside	25.97% upside

Epizyme (NASDAQ:EPZM) Consensus Price Target History

Price Target History for Epizyme (NASDAQ:EPZM)

Epizyme (NASDAQ:EPZM) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/14/2018	Wedbush	Reiterated Rating	Outperform	$26.00 -> $25.00	High
3/14/2018	Leerink Swann	Boost Price Target	Outperform -> Outperform	$22.00 -> $24.00	High
3/14/2018	SunTrust Banks	Reiterated Rating	Buy	$27.00	High
2/1/2018	Roth Capital	Initiated Coverage	Buy	$24.00	Medium
1/24/2018	Jefferies Group	Reiterated Rating	Buy -> Buy	$25.00	Low
1/10/2018	Morgan Stanley	Initiated Coverage	Overweight -> Overweight	$20.00	High
12/12/2017	Oppenheimer	Set Price Target	Buy	$26.00	Medium
12/12/2017	Cann	Reiterated Rating	Buy	$26.00	Medium
11/2/2017	HC Wainwright	Reiterated Rating	Buy	$25.00	N/A
11/2/2017	Royal Bank of Canada	Downgrade	Outperform -> Sector Perform	$20.00 -> $16.00	N/A
6/16/2017	Citigroup	Boost Price Target	Buy	$20.00 -> $22.00	Low
6/7/2017	Cowen	Reiterated Rating	Buy		High
4/13/2017	CIBC	Reiterated Rating	Outperform -> Outperform		Low
11/6/2016	JMP Securities	Reiterated Rating	Buy		N/A
6/20/2016	Mizuho	Reiterated Rating	Buy	$18.00	N/A

(Data available from 4/23/2016 forward)

Epizyme (NASDAQ:EPZM) Earnings History and Estimates Chart

Earnings by Quarter for Epizyme (NASDAQ:EPZM)

Epizyme (NASDAQ:EPZM) Earnings Estimates

2018 EPS Consensus Estimate: ($2.44)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	5	($0.56)	($0.52)	($0.54)
Q2 2018	5	($0.68)	($0.53)	($0.59)
Q3 2018	5	($0.80)	($0.51)	($0.63)
Q4 2018	5	($0.97)	($0.46)	($0.67)

Epizyme (NASDAQ EPZM) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/7/2018		($0.55)					N/A
3/13/2018	Q4 2017	($0.57)	($0.52)	$0.11 million		View	Listen
11/1/2017	Q3 2017	($0.65)	($0.63)	$0.19 million		View	N/A
8/4/2017	Q2 2017	($0.56)	($0.48)	$3.95 million	$10.00 million	View	N/A
5/8/2017	Q1 2017	($0.63)	($0.56)	$0.49 million		View	N/A
3/9/2017	Q4 2016	($0.65)	($0.60)	$0.61 million	$0.48 million	View	Listen
11/3/2016	Q3	($0.60)	($0.42)	$0.57 million	$6.58 million	View	Listen
8/8/2016	Q2	($0.52)	($0.49)	$0.61 million	$0.47 million	View	Listen
5/9/2016	Q1	($0.53)	($0.41)	$0.58 million	$0.47 million	View	Listen
3/9/2016	Q415	($0.65)	($0.53)	$0.66 million	$0.56 million	View	Listen
11/9/2015	Q315	($0.59)	($0.56)	$8.75 million	$0.36 million	View	Listen
8/6/2015	Q215	($0.70)	($0.63)	$2.23 million	$0.74 million	View	Listen
4/28/2015	Q115	($0.99)	($1.75)	$6.48 million	$0.91 million	View	N/A
3/12/2015	Q414	($0.54)	($0.44)	$10.10 million	$10.35 million	View	Listen
11/6/2014	Q314	($0.54)	($0.58)	$7.00 million	$8.20 million	View	N/A
8/13/2014	Q214	($0.46)	($0.40)	$7.59 million	$9.50 million	View	N/A
5/13/2014	Q114	($0.48)	($0.22)	$7.67 million	$13.39 million	View	N/A
2/27/2014	Q413	($0.22)	$0.52	$9.00 million	$36.32 million	View	N/A
10/22/2013	Q3 2013	($0.36)	($0.34)	$8.07 million	$8.44 million	View	N/A
7/31/2013	Q2 2013	($0.26)	($0.25)	$11.27 million	$14.84 million	View	N/A

(Earnings results data provided by Zacks Investment Research)

Epizyme (NASDAQ:EPZM) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Epizyme (NASDAQ EPZM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 21.50%
Institutional Ownership Percentage: 85.77%

Insider Trading History for Epizyme (NASDAQ:EPZM)

Institutional Ownership by Quarter for Epizyme (NASDAQ:EPZM)

Epizyme (NASDAQ EPZM) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/5/2018	Matthew Ros	COO	Sell	72,264	$16.63	$1,201,750.32	74,867
10/24/2017	Peter Tai-Ching Ho	Insider	Sell	15,000	$16.44	$246,600.00	23,123
9/25/2017	Peter Tai-Ching Ho	Insider	Sell	15,000	$16.81	$252,150.00	23,123
9/18/2017	David M Mott	Director	Buy	200,000	$15.25	$3,050,000.00	6,000
8/24/2017	Peter Tai-Ching Ho	Insider	Sell	15,000	$15.68	$235,200.00	22,228
7/24/2017	Peter Tai-Ching Ho	Insider	Sell	15,000	$13.44	$201,600.00	22,228
6/30/2017	Andrew E Singer	CFO	Sell	3,024	$15.50	$46,872.00	40,529
6/26/2017	Peter Tai-Ching Ho	Insider	Sell	15,000	$14.87	$223,050.00	22,228
6/6/2017	Robert A Copeland	Insider	Sell	2,500	$13.45	$33,625.00	34,038
5/25/2017	Peter Tai-Ching Ho	Insider	Sell	15,000	$16.11	$241,650.00	22,228
5/2/2017	Robert A Copeland	Insider	Sell	5,000	$17.44	$87,200.00	36,538
4/4/2017	Robert A Copeland	Insider	Sell	5,000	$16.36	$81,800.00	33,538
3/31/2017	Andrew E Singer	CFO	Sell	2,013	$17.09	$34,402.17	36,175
1/9/2017	Andrew E Singer	CFO	Sell	1,013	$12.04	$12,196.52	33,506
12/9/2016	Andrew E Singer	CFO	Sell	1,013	$11.03	$11,173.39	32,060
11/9/2016	Andrew E Singer	CFO	Sell	1,013	$10.40	$10,535.20	30,613
10/10/2016	Andrew E Singer	CFO	Sell	1,013	$9.72	$9,846.36	29,167
9/9/2016	Andrew E Singer	CFO	Sell	1,013	$7.55	$7,648.15	27,721
8/9/2016	Andrew E Singer	CFO	Sell	1,013	$9.05	$9,167.65	26,274
8/1/2016	Robert A Copeland	Insider	Sell	4,000	$10.37	$41,480.00	35,538
7/11/2016	Andrew E Singer	CFO	Sell	1,013	$10.36	$10,494.68	24,828
7/5/2016	Robert A Copeland	Insider	Sell	4,000	$10.03	$40,120.00	4,000
6/9/2016	Andrew E Singer	CFO	Sell	1,013	$12.49	$12,652.37	23,382
4/12/2016	Andrew E Singer	CFO	Sell	1,013	$12.42	$12,581.46	20,489
3/9/2016	Andrew E Singer	CFO	Sell	1,006	$9.33	$9,385.98	19,036
2/29/2016	Peter Tai-Ching Ho	Insider	Buy	636	$7.47	$4,750.92
2/10/2016	Andrew E. Singer	CFO	Sell	12,158	$9.54	$115,987.32	17,354
1/12/2016	Bay City Capital Fund V Co-Inv	Major Shareholder	Buy	555,555	$9.00	$4,999,995.00
1/12/2016	David M Mott	Director	Buy	1,111,111	$9.00	$9,999,999.00
1/4/2016	Robert A. Copeland	insider	Sell	4,185	$15.58	$65,202.30
12/30/2015	Robert J. Gould	Director	Sell	32,108	$18.01	$578,265.08
12/9/2015	Peter Tai-Ching Ho	Insider	Buy	1,000	$14.69	$14,690.00
12/7/2015	Robert A. Copeland	insider	Sell	4,185	$13.82	$57,836.70
11/9/2015	Robert A. Copeland	insider	Sell	4,185	$16.26	$68,048.10
10/5/2015	Robert A. Copeland	insider	Sell	4,185	$14.43	$60,389.55
9/8/2015	Robert A. Copeland	insider	Sell	4,185	$19.58	$81,942.30
9/8/2015	Robert J. Gould	CEO	Sell	60,000	$19.86	$1,191,600.00
7/6/2015	Robert A Copeland	Insider	Sell	8,371	$22.86	$191,361.06
7/6/2015	Robert J Gould	CEO	Sell	60,000	$23.22	$1,393,200.00
5/5/2015	Peter Tai-Ching Ho	Insider	Buy	800	$16.36	$13,088.00
12/2/2014	Peter Tai-Ching Ho	Insider	Buy	1,000	$21.17	$21,170.00
11/17/2014	Robert A Copeland	EVP	Sell	20,000	$22.68	$453,600.00
11/3/2014	Robert A Copeland	EVP	Sell	20,000	$25.47	$509,400.00
11/3/2014	Robert J Gould	CEO	Sell	30,000	$24.95	$748,500.00
10/7/2014	Robert A Copeland	EVP	Sell	20,000	$26.90	$538,000.00
10/1/2014	Robert J Gould	CEO	Sell	30,000	$26.28	$788,400.00
10/1/2014	Stephen Garbacz	Insider	Sell	868	$27.06	$23,488.08
9/22/2014	Robert A Copeland	EVP	Sell	20,000	$25.55	$511,000.00
9/15/2014	Eric Hedrick	Insider	Sell	2,000	$28.67	$57,340.00
9/4/2014	Carl Goldfischer	Director	Sell	4,000	$35.14	$140,560.00
8/26/2014	Bay City Capital Llc	Major Shareholder	Sell	200,000	$35.14	$7,028,000.00
8/25/2014	Bay City Capital Llc	Major Shareholder	Sell	366,666	$33.98	$12,459,310.68
8/18/2014	Robert A Copeland	EVP	Sell	10,830	$36.07	$390,638.10
8/15/2014	Ryan D Drant	Major Shareholder	Sell	4,061	$36.54	$148,388.94
8/4/2014	Jason P Rhodes	CFO	Sell	30,000	$29.74	$892,200.00
8/4/2014	Robert A Copeland	EVP	Sell	20,000	$29.42	$588,400.00
7/15/2014	Eric Hedrick	Insider	Sell	2,000	$31.35	$62,700.00
7/7/2014	Jason P Rhodes	CFO	Sell	30,000	$32.74	$982,200.00
7/1/2014	Robert J Gould	CEO	Sell	30,000	$31.53	$945,900.00
6/23/2014	Robert A Copeland	EVP	Sell	20,000	$28.42	$568,400.00
6/16/2014	Eric Hedrick	Insider	Sell	2,000	$26.42	$52,840.00
6/16/2014	Robert A Copeland	EVP	Sell	25,012	$26.38	$659,816.56
6/2/2014	Robert J Gould	CEO	Sell	30,000	$22.20	$666,000.00
5/19/2014	Robert Copeland	EVP	Sell	5,000	$22.28	$111,400.00	17,561
5/5/2014	Jason Rhodes	CFO	Sell	30,000	$21.53	$645,900.00	46,000
5/5/2014	Robert Copeland	EVP	Sell	10,000	$21.29	$212,900.00	20,011
5/1/2014	Robert Gould	CEO	Sell	30,000	$21.91	$657,300.00
4/28/2014	Robert Copeland	EVP	Sell	13,800	$20.73	$286,074.00	24,911
4/7/2014	Jason Rhodes	CFO	Sell	25,000	$20.05	$501,250.00	34,000
4/7/2014	Robert Gould	CEO	Sell	30,000	$20.22	$606,600.00
2/10/2014	Celgene European Investment Co	major shareholder	Buy	340,000	$29.25	$9,945,000.00
1/6/2014	Jason Rhodes	CFO	Sell	10,000	$20.19	$201,900.00	4,000
12/16/2013	Robert Copeland	EVP	Sell	4,600	$21.21	$97,566.00	53,544
12/2/2013	Robert Copeland	EVP	Sell	5,000	$20.70	$103,500.00	53,544
11/15/2013	M James Barrett	major shareholder	Buy	406,500	$19.68	$7,999,920.00
6/5/2013	David M Mott	Director	Buy	400,000	$15.00	$6,000,000.00
6/5/2013	Venture Fund I L.P. Astellas	Major Shareholder	Buy	15,333	$15.00	$229,995.00

(Data available from 1/1/2013 forward)

Epizyme (NASDAQ EPZM) News Headlines

Source:

Date	Headline
	-$0.54 Earnings Per Share Expected for Epizyme (EPZM) This Quarter www.americanbankingnews.com - April 22 at 3:08 AM
	Why Is Epizyme (EPZM) Down 18% Since Its Last Earnings Report? www.zacks.com - April 12 at 9:26 AM
	Epizyme's (EPZM) "Buy" Rating Reiterated at HC Wainwright www.americanbankingnews.com - April 12 at 12:29 AM
	Epizyme (EPZM) Publishes Tazemetostat Phase I Data, Stock Up finance.yahoo.com - April 11 at 5:03 PM
	Epizyme (EPZM) Reports Publication of Tazemetostat Phase 1 Clinical Data in The Lancet Oncology www.streetinsider.com - April 10 at 5:05 PM
	Epizyme (EPZM) Downgraded to "Hold" at BidaskClub www.americanbankingnews.com - April 10 at 10:25 AM
	ValuEngine Downgrades Epizyme (EPZM) to Strong Sell www.americanbankingnews.com - April 10 at 12:32 AM
	Epizyme (EPZM) Upgraded by Zacks Investment Research to "Buy" www.americanbankingnews.com - April 7 at 9:13 AM
	Epizyme (EPZM) Expected to Announce Quarterly Sales of $750,000.00 www.americanbankingnews.com - April 7 at 4:43 AM
	BRIEF-Epizyme Inc Files For Potential Mixed Shelf, Size Not Disclosed www.reuters.com - April 6 at 9:00 AM
	Zacks: Analysts Anticipate Epizyme (EPZM) Will Post Earnings of -$0.54 Per Share www.americanbankingnews.com - April 5 at 5:28 AM
	Epizyme (EPZM) Given Average Rating of "Buy" by Analysts www.americanbankingnews.com - April 5 at 3:24 AM
	Epizyme (EPZM) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - April 3 at 11:02 AM
	Epizyme (EPZM) Rating Lowered to Sector Perform at Royal Bank of Canada www.americanbankingnews.com - April 2 at 8:40 AM
	Epizyme (EPZM) Given Buy Rating at Cann www.americanbankingnews.com - April 2 at 8:31 AM
	Epizyme (EPZM) Rating Reiterated by HC Wainwright www.americanbankingnews.com - April 1 at 11:24 PM
	Epizyme (EPZM) Rating Lowered to Sell at ValuEngine www.americanbankingnews.com - April 1 at 7:35 PM
	Edited Transcript of EPZM earnings conference call or presentation 13-Mar-18 12:30pm GMT finance.yahoo.com - April 1 at 8:49 AM
	Zacks Investment Research Lowers Epizyme (EPZM) to Sell www.americanbankingnews.com - March 30 at 10:02 PM
	Epizyme (EPZM) Earns Overweight Rating from Analysts at Morgan Stanley www.americanbankingnews.com - March 29 at 3:01 PM
	Epizyme (EPZM) Upgraded at BidaskClub www.americanbankingnews.com - March 24 at 10:59 AM
	Epizyme Inc (EPZM) Expected to Post Earnings of -$0.54 Per Share www.americanbankingnews.com - March 19 at 3:06 AM
	Wedbush Weighs in on Epizyme Inc's Q1 2018 Earnings (EPZM) www.americanbankingnews.com - March 19 at 1:54 AM
	Epizyme (EPZM) Rating Increased to Buy at BidaskClub www.americanbankingnews.com - March 17 at 6:14 PM
	Epizyme (EPZM) Downgraded by Zacks Investment Research to Hold www.americanbankingnews.com - March 16 at 12:04 PM
	Epizyme Inc Forecasted to Earn Q2 2018 Earnings of ($0.59) Per Share (EPZM) www.americanbankingnews.com - March 16 at 9:06 AM
	Epizyme (EPZM) Reports Narrower-than-Expected Loss in Q4 - Nasdaq www.nasdaq.com - March 16 at 8:54 AM
	Oppenheimer Weighs in on Epizyme Inc's Q1 2018 Earnings (EPZM) www.americanbankingnews.com - March 16 at 8:40 AM
	Epizyme Inc to Post Q1 2018 Earnings of ($0.54) Per Share, Leerink Swann Forecasts (EPZM) www.americanbankingnews.com - March 16 at 8:37 AM
	FY2022 EPS Estimates for Epizyme Inc Reduced by Analyst (EPZM) www.americanbankingnews.com - March 15 at 3:10 PM
	Epizyme (EPZM) Upgraded at Zacks Investment Research www.americanbankingnews.com - March 15 at 12:51 PM
	FY2018 EPS Estimates for Epizyme Inc Decreased by Analyst (EPZM) www.americanbankingnews.com - March 15 at 9:28 AM
	Epizyme (EPZM) Given New $24.00 Price Target at Leerink Swann www.americanbankingnews.com - March 14 at 9:02 PM
	Wedbush Lowers Epizyme (EPZM) Price Target to $25.00 www.americanbankingnews.com - March 14 at 9:02 PM
	Epizyme (EPZM) Rating Reiterated by SunTrust Banks www.americanbankingnews.com - March 14 at 9:02 PM
	Epizyme (EPZM) Reports Narrower-than-Expected Loss in Q4 www.msn.com - March 14 at 6:31 PM
	Top Analyst Upgrades and Downgrades: Abercrombie, Altria, Century Aluminum, DSW, Ford, Quest Diagnostics, Sunoco and More 247wallst.com - March 14 at 9:22 AM
	Epizyme (EPZM) Releases Earnings Results, Beats Estimates By $0.06 EPS www.americanbankingnews.com - March 13 at 9:36 AM
	Epizyme Reports Fourth Quarter and Full Year 2017 Operating Results and 2018 Milestones finance.yahoo.com - March 13 at 8:59 AM
	Epizyme, Inc. to Host Earnings Call finance.yahoo.com - March 13 at 8:59 AM
	Epizyme (EPZM) Reports Narrower-than-Expected Q4 Loss finance.yahoo.com - March 13 at 8:58 AM
	Epizyme Appoints Oncology Industry Leader Michael Giordano, M.D., to its Board of Directors finance.yahoo.com - March 12 at 6:09 PM
	Epizyme Inc (EPZM) Receives Consensus Rating of "Buy" from Analysts www.americanbankingnews.com - March 11 at 4:28 AM
	Should You Buy Epizyme (EPZM) Ahead of Earnings? - Nasdaq www.nasdaq.com - March 9 at 6:13 PM
	Should You Buy Epizyme (EPZM) Ahead of Earnings? www.zacks.com - March 9 at 9:04 AM
	Epizyme (EPZM) and Insmed (INSM) Head-To-Head Comparison www.americanbankingnews.com - March 8 at 5:11 PM
	Epizyme (EPZM) Downgraded by ValuEngine to Sell www.americanbankingnews.com - March 4 at 7:16 PM
	Epizyme (EPZM) Upgraded by BidaskClub to "Buy" www.americanbankingnews.com - March 3 at 12:00 PM
	Hudson Bay Capital Management LP Takes $1.57 Million Position in Epizyme Inc (EPZM) www.americanbankingnews.com - March 2 at 12:57 PM
	Epizyme Announces Date of Fourth Quarter and Full Year 2017 Results Conference Call and Upcoming Presentation ... - GlobeNewswire (press release) globenewswire.com - March 1 at 8:39 AM

Epizyme (NASDAQ:EPZM) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Epizyme (NASDAQ:EPZM) Income Statement, Balance Sheet and Cash Flow Statement

Epizyme (NASDAQ EPZM) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff